CORRECTION -- Anpac Bio, USA
November 11 2021 - 2:19AM
In its press release dated November 9, 2021 entitled “AnPac Bio
Announces Pricing of Approximately $2.9 Million Underwritten Public
Offering of American Depositary Shares”, the dollar size of the
offering and the number of American Depositary Shares being sold
included the exercise of the over-allotment option rather than just
the base offering. The expected closing date has been corrected to
be November 15, 2021. A corrective press release is below.
AnPac Bio Announces Pricing of Approximately $2.5
Million Underwritten Public Offering of American Depositary
Shares
AnPac Bio-Medical Science Co., Ltd. (NASDAQ:
ANPC, the “Company”), a biotechnology company with operations in
China and the United States focusing on early cancer screening and
detection, today announced the pricing of an underwritten public
offering of 1,132,111 of its American Depositary Shares (“ADSs” or
“shares”) at a public offering price of $2.22 per share, for gross
proceeds to the Company of approximately $2.5 million, before
deducting the underwriting discount and other offering expenses
payable by the Company. In connection with the offering, the
Company granted to the underwriter the option to purchase up to an
additional 169,817 shares at the public offering price with the
option exercisable within 45 days of the closing of the
offering.
EF Hutton, division of Benchmark Investments,
LLC is acting as the sole book-running manager for the
offering.
The offering is expected to close on or about
November 15, 2021, subject to customary closing conditions.
The shares of ADSs described above are being
offered by AnPac Bio-Medical Science Co., Ltd. pursuant to a
"shelf" registration statement on Form F-3 (File No. 333-256630)
that became effective with the Securities and Exchange Commission
(SEC) on June 7, 2021, the base prospectus contained therein and an
accompanying prospectus supplement. The prospectus supplement
describing the terms of the public offering will be filed with the
SEC and will form a part of the effective registration
statement.
Copies of the prospectus supplement and the
accompanying prospectus relating to this offering may be obtained,
when available, on the SEC’s website at http://www.sec.gov or by
contacting EF Hutton, division of Benchmark Investments, LLC
Attention: Syndicate Department, 590 Madison Avenue, 39th Floor,
New York, NY 10022, by email at syndicate@efhuttongroup.com, or by
telephone at (212) 404-7002.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About AnPac BioAnPac Bio is a
biotechnology company focused on early cancer screening and
detection, with 142 issued patents as of March 31, 2021. For more
information, please visit: https://www.AnPacBio.com/.
Forward-Looking StatementsThis
press release contains statements that constitute “forward-looking
statements,” including with respect to the Company’s proposed
offering. No assurance can be given that the offering discussed
above will be completed on the terms described, or at all, or that
the net proceeds of the offering will be used as indicated.
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of the Company, including those set
forth in the Risk Factors section of the Company’s registration
statement and preliminary prospectus supplement and prospectus for
the offering filed with the SEC. Copies are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
For investor and media inquiries, please
contact:
Company:Phil Case, Marketing and Investor RelationsPhone:
+1-267-810-6776 (US)Email: phil_case@AnPacBio.com
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2024 to May 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From May 2023 to May 2024